{
    "clinical_study": {
        "@rank": "58626", 
        "arm_group": [
            {
                "arm_group_label": "Group RBLF", 
                "arm_group_type": "Active Comparator", 
                "description": "receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid)."
            }, 
            {
                "arm_group_label": "Group RA", 
                "arm_group_type": "Active Comparator", 
                "description": "receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid)."
            }
        ], 
        "brief_summary": {
            "textblock": "The eradication rates of first-line treatment for Helicobacter pylori(Hp) infection are not\n      satisfactory. The study aims to compare the efficacy and safety between quadruple therapy\n      with furazolidone and dual therapy with high doses of amoxicillin as rescue regimens for Hp."
        }, 
        "brief_title": "Quadruple Therapy Versus Dual Therapy as Rescue Regimens for Helicobacter Pylori Infection", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Rescue Therapy for Helicobacter Pylori", 
        "condition_browse": {
            "mesh_term": "Helicobacter Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged from 18 to 80 years, who presented with upper gastrointestinal symptoms\n             and endoscopically proven H. pylori-positive non-ulcer dyspepsia, were recruited into\n             the study.\n\n        Exclusion Criteria:\n\n          -  patients with peptic ulcer,\n\n          -  previous H. pylori eradication treatment,\n\n          -  previous gastric surgery,\n\n          -  pregnancy,\n\n          -  lactation,\n\n          -  major systemic diseases,\n\n          -  receipt of anti-secretory therapy,\n\n          -  antibiotics or bismuth in the preceding four weeks, or - allergy to any one of the\n             medications in the regimen."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "114", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01805934", 
            "org_study_id": "rjyyxhk2013-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group RBLF", 
                "description": "The patients in Group RBLF will receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).", 
                "intervention_name": "RBLF", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group RA", 
                "description": "The patients in Group RA will be sent to a penicillin skin test before treatment except they were given penicillin before. They will receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).", 
                "intervention_name": "RA", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amoxicillin", 
                "Furazolidone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Helicobacter pylori, rescue, quadruple therapy\uff0cdual therapy", 
        "lastchanged_date": "March 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai"
                }, 
                "name": "Shanghai Renji Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Quadruple Therapy With Furazolidone Versus Dual Therapy With High Doses of Amoxicillin as Rescue Regimens for Helicobacter Pylori Infection", 
        "other_outcome": {
            "measure": "13C-urea breath test", 
            "safety_issue": "Yes", 
            "time_frame": "baseline"
        }, 
        "overall_official": {
            "affiliation": "Renji Hospital, Shanghai Jiao Tong University School of Medicine", 
            "last_name": "xiaobo Li, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "When the outcome of 13C-urea breath test is more than 4%, the helicobacter pylori infection is still exist(positive).", 
            "measure": "13C-urea breath test", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks after treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01805934"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Jiao Tong University School of Medicine", 
            "investigator_full_name": "Xiaobo Li", 
            "investigator_title": "Xiaobo Li", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "scale analysis of drug safety", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks after treatment"
        }, 
        "source": "Shanghai Jiao Tong University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai Jiao Tong University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}